BOCOM International has raised the target price for AKESO (09926) from HK$115 to HK$140, reaffirming its "buy" recommendation. Near-term catalysts include the overseas submission and comprehensive data release for the HARMONi study, alongside the presentation of AK112-306 research at ESMO 2025. Fourth-quarter reimbursement negotiations for multiple products and indications, as well as progress in ADC and other early-stage initiatives, are also pivotal drivers.
Ivonescimab, developed by AKESO, is accelerating its overseas registration and indication expansion, demonstrating emerging potential as a next-generation immune-oncology cornerstone. The drug's approval outlook abroad appears promising. This year, AKESO launched several Phase III trials in mainland China, addressing high-need patient groups with constrained treatment options. The trajectory for ivonescimab to supplant PD-(L)1 monotherapy as a foundational I/O agent is increasingly evident. Consequently, the PoS-adjusted peak sales forecast for ivonescimab in China has been revised upward to RMB 7.1 billion.
Over the next 2-3 years, assets such as cadonilimab could follow paths to overseas registration or BD deals. Vigilance on data disclosures and clinical program launches is advised.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.